Testing for Rare Genomic Alterations in Colorectal Cancer
Michael J. Overman, MD, discusses the advances in testing for rare genomic alterations in colorectal cancer.
Michael J. Overman, MD, professor at The University of Texas MD Anderson Cancer Center, and committee vice chair at The University of Texas MD Anderson Cancer Center – ECMS in Houston, Texas, discusses the advances in testing for rare genomic alterations in colorectal cancer (CRC).
Historically, experts in the field focused on KRAS mutational status, RAS status, and anti-EGFR therapies, Overman explained. Over the years, mindsets have expanded to also consider alterations like BRAF, HER2, and prognostic factors like mismatch repair deficiency. Many of these are now mandated for testing in CRC, Overman says.
There are also rare genomic alterations that fall under the gene fusion category that have available treatment options and should be considered for testing, according to Overman.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
